Trials / Withdrawn
WithdrawnNCT02182622
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Ib Dose Finding Study of LDE225 Plus Docetaxel/Prednisone in Patients With Advanced or Metastatic Castration Resistant Prostate Cancer Who Experience Disease Progression After Receiving Docetaxel
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Martin Gutierrez · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to first determine the highest dose of LDE225 combined wtih Docetaxel and Prednisone that can be given that does not cause unacceptable side effects when given to patients with castrate resistant prostate cancer who failed previous docetaxel therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | |
| DRUG | Prednisone | |
| DRUG | LDE225 |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2014-07-08
- Last updated
- 2019-06-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02182622. Inclusion in this directory is not an endorsement.